Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophag...

بواسطة Lorenzen, S, Pauligk, C, Homann, N, Schmalenberg, H, Jäger, E, Al-Batran, S-E
منشور في 2013

Anthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trials

بواسطة Al-Batran, S-E, Güntner, M, Pauligk, C, Scholz, M, Chen, R, Beiss, B, Stopatschinskaja, S, Lerbs, W, Harbeck, N, Jäger, E
منشور في 2010

Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial

بواسطة Atmaca, A, Al-Batran, S-E, Maurer, A, Neumann, A, Heinzel, T, Hentsch, B, Schwarz, S E, Hövelmann, S, Göttlicher, M, Knuth, A, Jäger, E
منشور في 2007

New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma

بواسطة Wedel, S A, Sparatore, A, Soldato, P D, Al-Batran, S-E, Atmaca, A, Juengel, E, Hudak, L, Jonas, D, Blaheta, R A
الحاوية / القاعدة J Cell Mol Med (2008)

PD-038 Exposure-Response relationship of second-line ramucirumab in East Asian patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study

بواسطة Kim, T.Y., Yen, C.-J., Al-Batran, S.-E., Gao, L., Ferry, D., Hsu, Y., Cheng, R., Orlando, M., Ohtsu, A.
الحاوية / القاعدة Ann Oncol (2016)

A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors

بواسطة Haense, N., Atmaca, A., Pauligk, C., Steinmetz, K., Marmé, F., Haag, G. M., Rieger, M., Ottmann, O. G., Ruf, P., Lindhofer, H., Al-Batran, S.-E.
الحاوية / القاعدة BMC Cancer (2016)

The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial

بواسطة Al-Batran, S-E, Bischoff, J, von Minckwitz, G, Atmaca, A, Kleeberg, U, Meuthen, I, Morack, G, Lerbs, W, Hecker, D, Sehouli, J, Knuth, A, Jager, E
منشور في 2006

Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone

بواسطة Wimberger, P., Gilet, H., Gonschior, A-K., Heiss, M. M., Moehler, M., Oskay-Oezcelik, G., Al-Batran, S-E., Schmalfeldt, B., Schmittel, A., Schulze, E., Parsons, S. L.
منشور في 2012

LUD 00-009: Phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer

بواسطة Bender, Armin, Karbach, Julia, Neumann, Antje, Jäger, Dirk, Al-Batran, Salah E., Atmaca, Akin, Weidmann, Eckhart, Biskamp, Melina, Gnjatic, Sacha, Pan, Linda, Hoffman, Eric, Old, Lloyd J., Knuth, Alexander, Jäger, Elke
منشور في 2007

A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer

بواسطة Atmaca, A, Al-Batran, S-E, Werner, D, Pauligk, C, Güner, T, Koepke, A, Bernhard, H, Wenzel, T, Banat, A-G, Brueck, P, Caca, K, Prasnikar, N, Kullmann, F, Günther Derigs, H, Koenigsmann, M, Dingeldein, G, Neuhaus, T, Jäger, E
منشور في 2013

Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial

بواسطة Huebner, G, Link, H, Kohne, C H, Stahl, M, Kretzschmar, A, Steinbach, S, Folprecht, G, Bernhard, H, Al-Batran, S E, Schoffski, P, Burkart, C, Kullmann, F, Otremba, B, Menges, M, Hoffmann, M, Kaiser, U, Aldaoud, A, Jahn, A
منشور في 2009

Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated ga...

بواسطة Al-Batran, S.-E., Van Cutsem, E., Oh, S. C., Bodoky, G., Shimada, Y., Hironaka, S., Sugimoto, N., Lipatov, O. N., Kim, T.-Y., Cunningham, D., Rougier, P., Muro, K., Liepa, A. M., Chandrawansa, K., Emig, M., Ohtsu, A., Wilke, H.
الحاوية / القاعدة Ann Oncol (2016)

PD-027 BRAF mutant and RAS mutant patients treated with FOLFIRI plus Bevacizumab or FOLFIRI plus Cetuximab. Role of ETS and molecular markers in FIRE-3 (AIO KRK-0306)

بواسطة Stintzing, S., Fischer von Weikersthal, L., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., Kullmann, F., Stauch, M., Hielscher, J., Lerch, M., Scheithauer, W., Jagenburg, A., Held, S., Modest, D., Jung, A., Kirchner, T., Heinemann, V.
الحاوية / القاعدة Ann Oncol (2016)

A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study

بواسطة Türeci, O, Sahin, U, Schulze-Bergkamen, H, Zvirbule, Z, Lordick, F, Koeberle, D, Thuss-Patience, P, Ettrich, T, Arnold, D, Bassermann, F, Al-Batran, S E, Wiechen, K, Dhaene, K, Maurus, D, Gold, M, Huber, C, Krivoshik, A, Arozullah, A, Park, J W, Schuler, M
الحاوية / القاعدة Ann Oncol (2019)

Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: p...

بواسطة Bang, Y -J, Ruiz, E Yañez, Van Cutsem, E, Lee, K -W, Wyrwicz, L, Schenker, M, Alsina, M, Ryu, M -H, Chung, H -C, Evesque, L, Al-Batran, S -E, Park, S H, Lichinitser, M, Boku, N, Moehler, M H, Hong, J, Xiong, H, Hallwachs, R, Conti, I, Taieb, J
الحاوية / القاعدة Ann Oncol (2018)